Loading
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Previous close
$4.17
+$0.21 · +5.30%
Pre-market
$4.17
$0.00 · 0.00%
Oct 8, 5:44 AM ET
Regular session · ET · Market data may be delayed.
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Day range
Current $4.17
52-week range
Current $4.17
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
41
Mixed
Risk
53
Elevated Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Day range
Current $4.17
52-week range
Current $4.17
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM6.11M0.01%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF4.19M0.00%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO2.21M0.02%14.25B USD0.24%$355.37-1.43%
Vanguard Russell 2000 ETFVTWO1.88M0.01%18B USD0.06%$112.21-1.26%
iShares Micro-Cap ETFIWC730.81K0.05%1.33B USD0.60%$183.36-1.09%
ALPS Medical Breakthroughs ETFSBIO503.75K0.27%188.26M USD0.50%$54.13-0.46%
Vanguard Russell 2000 Growth ETFVTWG354.61K0.02%1.7B USD0.06%$259.28-1.46%
iShares Russell 2500 ETFSMMD128.59K0.00%4.06B USD0.23%$85.85-1.46%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
